荃信生物-B2025中期报告

2025中期報告 Contents 2Corporate Information6Financial Highlights7Management Discussion and Analysis34Other Information53Auditor’s Independent Review Report tothe Board of Directors55Consolidated Statement of Profit or Loss andOther Comprehensive Income57Consolidated Statement of Financial Position59Consolidated Statement of Changes in Equity61Condensed Consolidated Cash Flow Statement63Notes to the Unaudited Interim Financial Report92Definitions and Glossary of Technical Terms Corporate Information BOARD OF DIRECTORS Executive Directors Mr. Qiu Jiwan(Chairman and General Manager)Mr. Wu YiliangMr. Lin Weidong Non-executive Directors Mr. Yu XiMr. Wu Zhiqiang Independent Non-Executive Directors Dr. Zou ZhongmeiDr. Ling JianqunMr. Fung Che Wai, Anthony(Lead independent non-executiveDirector) SUPERVISORS Mr. Ye XiangDr. Ding ChaoMs. Wang Yujiao JOINT COMPANY SECRETARIES Mr. Hu YanbaoMs. Tang King Yin AUDIT COMMITTEE Mr. Fung Che Wai, Anthony(Chairman)Mr. Wu ZhiqiangDr. Ling Jianqun REMUNERATION AND APPRAISAL COMMITTEE Dr. Ling Jianqun(Chairman)Dr. Zou ZhongmeiMr. Qiu Jiwan Corporate Information NOMINATION COMMITTEE Mr. Qiu Jiwan(Chairman)Dr. Zou ZhongmeiDr. Ling Jianqun STRATEGY AND DEVELOPMENT COMMITTEE Mr. Qiu Jiwan(Chairman)Mr. Yu XiDr. Zou Zhongmei AUTHORISED REPRESENTATIVES Mr. Qiu JiwanMs. Tang King Yin AUDITOR 108 KPMGPublic Interest Entity Auditor registered in accordance withthe Accounting and Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater Road, CentralHong Kong LEGAL ADVISORS as to Hong Kong laws 15323203-3207 Jingtian & Gongcheng LLPSuites 3203-3207, 32/FEdinburgh Tower, The Landmark15 Queen’s Road CentralCentralHong Kong as to PRC laws JC MASTER LAW (TAI ZHOU) OFFICES16/F, High-tech Office BuildingMedical New and High-tech ZoneTaizhou, JiangsuPRC 16 Corporate Information COMPLIANCE ADVISER 2920 Somerley Capital Limited20/F, China Building29 Queen’s Road CentralHong Kong HEADQUARTERS AND REGISTERED OFFICEIN THE PRC 90711310 Room 1310, Building 1No. 907 Yaocheng AvenueTaizhou, JiangsuPRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG 33191912 Room 1912, 19/FLee Garden One33 Hysan AvenueCauseway BayHong Kong PRINCIPAL BANKS Shanghai Pudong Development Bank Taizhou Branch 215 No. 215 North Youth RoadTaizhou, JiangsuPRC Bank of China Taizhou Branch 329 No. 329 South Hailing RoadTaizhou, JiangsuPRC China Merchants Bank Taizhou Branch 293-10 No. 293-10 South Gulou RoadTaizhou, JiangsuPRC Corporate Information H HONG KONG H SHARE REGISTRAR ANDTRANSFER OFFICE 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong STOCK NAMEQyuns Therapeutics Co., Ltd. 2509 STOCK CODE2509 www.qyuns.net COMPANY’S WEBSITE www.qyuns.net Financial Highlights Management Discussion and Analysis OVERVIEW 2015 Founded in 2015, we are a biotech company exclusively focusedon biologic therapies for autoimmune and allergic diseases,fully covering dermatology, respiratory, gastroenterology andrheumatology. With an integrated strategy encompassing R&D,production and commercial collaboration, we aim to fully unlockthe commercial value of our pipeline products, form a progressiveR&D and commercialisation matrix, and continue to solidifyour leading position in the autoimmune field and improve thetreatment standards for related diseases through the efficientdevelopment of a series of bispecific antibody products. ®QX005NIL-4R2025320258(PN)(AD)IIIQX002NIL-17AASIII20252BLAQX004N IL-23p19QX008NTSLPPsIIICOPDII As of the Latest Practicable Date, we have one commercialisedproduct, namely SAILEXIN, China’s first ustekinumab biosimilar.Two core products are progressing smoothly in development.In particular, QX005N (anti-IL-4RmAb) completed patientenrollment for the Phase III trial in China for prurigo nodularis(PN) and atopic dermatitis (AD) in March 2025 and August2025, respectively, with such trials expected to read out primaryendpoint data at the end of this year and early next year,respectively. QX002N (anti-IL-17A mAb) reached the primaryendpoint in the Phase III trial in China for ankylosing spondylitis(AS) in February 2025 and is planned for BLA submission withinthis year. QX004N (anti-IL-23p19 mAb) and QX008N (anti-TSLPmAb) are in Phase III clinical trial for psoriasis (Ps) and Phase IIclinical trial for chronic obstructive pulmonary disease (COPD) inChina, respectively, with partners accelerating their development.Such tiered product pipeline significantly strengthens our R&Dand commercialisation foundation, providing greater certainty forthe Company’s future growth. FICBIC Furthermore, leveraging our deep expertise in the autoimmunefield, we have efficiently developed a series of long-actingbispecific antibody products to address the shortcomings ofexisting therapies. With the continuous expansion of potentialfirst-in-class (FIC) and best-in-class (BIC) products in ourpipeline, the Company will speed